Voyager Therapeutics Aktie
WKN DE: A143XJ / ISIN: US92915B1061
02.01.2024 13:53:05
|
Voyager Therapeutics Enters Collaboration And Capsid License Agreement With Novartis Pharma
(RTTNews) - Voyager Therapeutics, Inc. (VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NVS) to advance potential gene therapies for Huntington's disease and spinal muscular atrophy. Voyager will provide Novartis a target-exclusive license to access Voyager's TRACER capsids and other intellectual property for the respective diseases. Also the companies will collaborate to advance a preclinical gene therapy candidate for Huntington's disease.
Novartis has agreed to pay Voyager $100 million of consideration up front, including a $20 million purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in milestones, as well as tiered royalties.
Shares of Voyager Therapeutics are up 29% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Voyager Therapeutics Incmehr Nachrichten
10.03.25 |
Ausblick: Voyager Therapeutics gewährt Anlegern Blick in die Bücher (finanzen.net) |
Analysen zu Voyager Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Novartis AG (Spons. ADRS) | 97,60 | 0,62% |
|
Voyager Therapeutics Inc | 3,00 | -0,53% |
|